Natasa Gisev1, Suzanne Nielsen2, Elena Cama2, Briony Larance2, Raimondo Bruno2,3, Louisa Degenhardt2. 1. National Drug and Alcohol Research Centre, UNSW, Australia, Sydney, NSW, 2052, Australia. n.gisev@unsw.edu.au. 2. National Drug and Alcohol Research Centre, UNSW, Australia, Sydney, NSW, 2052, Australia. 3. School of Medicine, University of Tasmania, Hobart, Australia.
Abstract
PURPOSE: The extent and factors associated with codeine use in the community remain poorly understood despite the widespread global use of codeine. The aim of this study was to examine the use of prescription and over-the-counter (OTC) codeine in Australia and identify the geographic and socio-demographic characteristics associated with prescription and OTC codeine use. METHODS: National sales data for prescription and OTC codeine (supplied by IMS Health) were used to estimate codeine utilisation (in pack sales and milligrammes) in Australia during 2013, mapped to Australian Bureau of Statistics (ABS) Statistical Local Areas (SLAs) and Remoteness Areas. Socio-demographic characteristics and total population estimates of SLAs were obtained from the ABS. SLA-level data on sex, age distribution, income, occupations involving physical labour and number of pharmacies were included in linear regression analyses to examine their association with total, prescription and OTC codeine use. RESULTS: In total, 27,780,234 packs of codeine were sold in Australia during 2013, equating to 12,376 kg. OTC codeine preparations accounted for 15,490,207 packs (55.8 %) or 4967.30 kg (40.1 %). Nationally, an estimated 1.24 packs (or 554.10 mg) of codeine were sold per person; utilisation was higher in more remote areas. SLAs with a higher percentage of low-income earning households had the highest rates of prescription codeine use (β 0.16, p < 0.001), whereas SLAs with a higher percentage of males had the highest rates of OTC codeine use (β 0.22, p < 0.001). CONCLUSIONS: Codeine use is common in Australia, with clear distinctions in the geographic and socio-demographic characteristics associated with prescription and OTC codeine use.
PURPOSE: The extent and factors associated with codeine use in the community remain poorly understood despite the widespread global use of codeine. The aim of this study was to examine the use of prescription and over-the-counter (OTC) codeine in Australia and identify the geographic and socio-demographic characteristics associated with prescription and OTC codeine use. METHODS: National sales data for prescription and OTC codeine (supplied by IMS Health) were used to estimate codeine utilisation (in pack sales and milligrammes) in Australia during 2013, mapped to Australian Bureau of Statistics (ABS) Statistical Local Areas (SLAs) and Remoteness Areas. Socio-demographic characteristics and total population estimates of SLAs were obtained from the ABS. SLA-level data on sex, age distribution, income, occupations involving physical labour and number of pharmacies were included in linear regression analyses to examine their association with total, prescription and OTC codeine use. RESULTS: In total, 27,780,234 packs of codeine were sold in Australia during 2013, equating to 12,376 kg. OTC codeine preparations accounted for 15,490,207 packs (55.8 %) or 4967.30 kg (40.1 %). Nationally, an estimated 1.24 packs (or 554.10 mg) of codeine were sold per person; utilisation was higher in more remote areas. SLAs with a higher percentage of low-income earning households had the highest rates of prescription codeine use (β 0.16, p < 0.001), whereas SLAs with a higher percentage of males had the highest rates of OTC codeine use (β 0.22, p < 0.001). CONCLUSIONS:Codeine use is common in Australia, with clear distinctions in the geographic and socio-demographic characteristics associated with prescription and OTC codeine use.
Entities:
Keywords:
Analgesics; Codeine; Drug utilisation; Non-prescription drugs; Opioids; Pharmacoepidemiology
Authors: K Henricson; A Carlsten; J Ranstam; G Rametsteiner; P Stenberg; A Wessling; A Melander Journal: Eur J Clin Pharmacol Date: 1999-10 Impact factor: 2.953
Authors: Amanda Roxburgh; Wayne D Hall; Lucinda Burns; Jennifer Pilgrim; Eva Saar; Suzanne Nielsen; Louisa Degenhardt Journal: Med J Aust Date: 2015-10-05 Impact factor: 7.738
Authors: Karin Zebenholzer; Colette Andree; Anita Lechner; Gregor Broessner; Christian Lampl; Gernot Luthringshausen; Albert Wuschitz; Sonja-Maria Obmann; Klaus Berek; Christian Wöber Journal: J Headache Pain Date: 2015-05-19 Impact factor: 7.277
Authors: Georgia C Richards; Jeffrey K Aronson; Brian MacKenna; Ben Goldacre; F D Richard Hobbs; Carl Heneghan Journal: Drug Saf Date: 2022-01-22 Impact factor: 5.606